ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Amicus and University of Pennsylvania to develop gene therapies

by Ryan Cross
October 14, 2018 | APPEARED IN VOLUME 96, ISSUE 41

 

Amicus Therapeutics is striking a partnership with the University of Pennsylvania to develop gene therapies for four rare metabolic conditions, including Pompe disease and Fabry disease. In the collaboration, Amicus will provide funds to Penn gene-therapy scientist James Wilson to develop and test preclinical adeno-associated virus therapies for the diseases. In return, Amicus may license therapies and technologies developed under the agreement. Precision BioSciences, a gene-editing company, made a similar research pact with Wilson’s lab earlier this year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment